Announcements Trials

Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Completed 11 Active not recruiting 2 Withdrawn 1 Terminated 1 Recruiting 1

Sponsor Class

OTHER 1 INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Triple Negative Breast Neoplasms 1 Breast Neoplasms 1

Interventions

pembrolizumab 184 Carboplatin 130 Paclitaxel 123 Gemcitabine 122 Docetaxel 96 Cyclophosphamide 89 Nivolumab 88 Cisplatin 87 Rituximab 71 Dexamethasone 68 Pemetrexed 64 Bevacizumab 64 Capecitabine 60 atezolizumab 54 fludarabine 49 Azacitidine 49 Fluorouracil 48 130-nm albumin-bound paclitaxel 43 venetoclax 41 Trastuzumab 41 Irinotecan 41 Cetuximab 40 Leucovorin 36 Ipilimumab 36 Erlotinib Hydrochloride 34 Fulvestrant 32 Cytarabine 32 avelumab 31 Oxaliplatin 31 Albumin-Bound Paclitaxel 31

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Terminated × INDUSTRY × reolysin × Clear all

NCT04102618 2022-08-15

AWARE-1

Oncolytics Biotech

Phase EARLY_PHASE1 Terminated

Breast Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡